The characteristics of torasemide - loop diuretic application in patients with compensated heart failure
- Authors: Ovchinnikov A.G1
-
Affiliations:
- Scientific dispensary department of A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation
- Issue: Vol 17, No 5 (2015)
- Pages: 26-32
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/94278
- ID: 94278
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
A. G Ovchinnikov
Scientific dispensary department of A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation
Email: artcardio@mail.ru
д-р мед. наук, Научно-Диспансерный Отдел ИКК им. А.Л.Мясникова ФГБУ РКНПК 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15a
References
- Yancy C, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 62: e147.
- Faris R, Flather M, Purcell H et al. Diuretics for heart failure. Cochrane Database Syst Rev 2006; 1: CD003838.
- Pitt B, Zannad F, Remme W.J et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
- Pitt B, Williams G, Remme W et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15: 79-87.
- Meta-Analysis Research Group in Echocardiography (MeRGE) AMI Collaborators. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta - analysis: Meta-Analysis Research Group in Echocardiography acute myocardial infarction. Circulation 2008; 117: 2591-8.
- Opie L, Kaplan N. Diuretics. In: L.Opie, B.Gersh (eds): Drugs for the heart (6th ed). Elsevier Saunders 2005; p. 80-103.
- Азизова А.Г., Овчинников А.Г., Агеев Ф.Т. Сравнительное влияние торасемида и фуросемида на клинический статус и диастолическую функцию левого желудочка у больных с компенсированной сердечной недостаточностью и высоким давлением наполнения левого желудочка. Сердечная недостаточность. 2011; 12: 326-32.
- Yamato M, Sasaki T, Honda К et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J 2003; 67: 384-90.
- López B, Querejeta R, Gonzalez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028-35.
- Uchida T, Yamanaga K, Kido H et al. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84 (Suppl. 2): 14-7.
- Uchida T, Yamanaga K, Nishikawa M et al. Anti - aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 26: 145-50.
- Goodfriend T, Ball D, Oelkers W, Bähr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63: 45-50.
- Cosín J, Díez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4: 507-13.
- Murray M et al. Open - label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111: 513-20.
- Lόpez B, González A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859-67.
- Ellison D. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001; 96: 132.
Supplementary files
